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Abstract: Blacks have different dominant polymorphisms in the vitamin D-binding protein (DBP)
gene that result in higher bioavailable vitamin D than whites. This study tested whether the lack
of association between 25-hydroxyvitamin D (25OHD) and multiple sclerosis (MS) risk in blacks
and Hispanics is due to differences in these common polymorphisms (rs7041, rs4588). We recruited
incident MS cases and controls (blacks 116 cases/131 controls; Hispanics 183/197; whites 247/267)
from Kaiser Permanente Southern California. AA is the dominant rs7041 genotype in blacks (70.0%)
whereas C is the dominant allele in whites (79.0% AC/CC) and Hispanics (77.1%). Higher 25OHD
levels were associated with a lower risk of MS in whites who carried at least one copy of the C allele
but not AA carriers. No association was found in Hispanics or blacks regardless of genotype. Higher
ultraviolet radiation exposure was associated with a lower risk of MS in blacks (OR = 0.06), Hispanics
and whites who carried at least one copy of the C allele but not in others. Racial/ethnic variations
in bioavailable vitamin D do not explain the lack of association between 25OHD and MS in blacks
and Hispanics. These findings further challenge the biological plausibility of vitamin D deficiency as
causal for MS.
Keywords: multiple sclerosis; vitamin D; polymorphisms; blacks; Hispanics
1. Introduction
Exposure to ultraviolet radiation (UVR) from sun exposure stimulates intradermal synthesis of
vitamin D and is the principal natural source of this vitamin. Higher lifetime UVR has been associated
with a decreased risk of multiple sclerosis (MS) in whites [1–4], and recently we reported similar
findings in blacks and Hispanics. However, higher serum 25-hydroxyvitamin D (25OHD) levels [1,4–6]
are associated with a reduced risk of MS only in whites. We and others have been unable to detect an
association between serum 25OHD levels and MS risk in blacks [5,7] or Hispanics [7]. Whether this is
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because serum 25OHD is not a good indicator of vitamin D status in non-whites or due to the many
vitamin D-independent immunological effects of UVR is unknown.
Blacks and Hispanics have lower 25OHD levels than whites, yet there is substantial evidence that
low 25OHD levels in blacks do not lead to any excess ill health consequences [8]. Recent studies of the
general population have argued that total serum 25OHD levels are a poor indicator of vitamin D status
in blacks and that bioavailable or ‘free’ 25OHD and/or its metabolites may be superior indicators [8,9].
Blacks have different dominant common polymorphisms in the vitamin D-binding protein gene
than whites that directly affect binding avidity and bioavailability of vitamin D metabolites. Vitamin
D-binding protein (DBP), among other functions, is the main transporter of 25OHD to target tissues [10].
Thus, it is biologically plausible that differences in these DBP polymorphisms could explain why we
were unable to detect an association between 25OHD and MS risk in blacks and Hispanics.
The primary purpose of the MS Sunshine study was to test the vitamin D-MS hypothesis in blacks
and Hispanics including variations in the gene that encodes DBP. The results presented herein address
whether high serum 25OHD, independent of UVR, reduces the risk of MS in those individuals that
carry the common DBP polymorphisms that are dominant in whites, regardless of race/ethnicity.
2. Materials and Methods
2.1. Study Population
Participants in the MS Sunshine Study were recruited from the Kaiser Permanente Southern
California (KPSC) membership between December 2011 and December 2014 via mailings and telephone
contact. KPSC is a large prepaid health maintenance organization with over 4 million members
representative of the general population in Southern California [11]. KPSC uses an integrated electronic
health record (EHR) system which includes all inpatient and outpatient encounters, diagnostic tests,
diagnoses and medications, as well as some demographic and behavioral characteristics. Data were
collected from the EHR and, after informed consent, structured in-person interview and a blood draw
for genotyping and 25OHD measurement (if not already available in the EHR). All subjects gave their
informed consent for inclusion before they participated in the study. The study was conducted in
accordance with the Declaration of Helsinki, and the protocol was approved by the KPSC institutional
review board (IRB 5962).
2.1.1. Case Identification
Incident cases with MS or clinically isolated syndrome (CIS) were identified using similar methods
as previously described [12,13]. Briefly, we searched EHRs monthly for first mention of ICD-9
diagnostic codes for MS or CIS. Diagnoses were confirmed by an MS specialist (ALG) according
to diagnostic criteria/consensus definitions for MS [14] or CIS [15,16]. Eligibility required diagnosis
of MS or CIS within the past 1.5 years or symptom onset within the past 3 years and age ≥18 years
(see Appendix A).
2.1.2. Control Selection
Once a case interview was completed, at least 1 control participant from the KPSC population,
matched to the case on race/ethnicity, date of birth (within 2 years), sex and home KPSC facility
(a surrogate measure for socioeconomic status) was identified from the EHR and recruited. The controls
were assigned the same index date as their matched case (symptom onset date).
2.2. Data Collection
Self-identified race/ethnicity was obtained from the interview. White, non-Hispanics were
classified as white; any black race regardless of ethnicity was classified as black; and those who
identified themselves as white, Hispanics were classified as Hispanics. Comparison with genetic
ancestry markers validated the accuracy of self-identified race/ethnicity.
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Covariates obtained from the interview included sun exposure during weekends and holidays
(leisure time) age 6 years to date of interview, places of residence since birth, smoking (never/ever)
and vitamin D supplement use defined as ≥600 IU daily at or within 3 months prior to 25OHD
measurement. Age was defined as age at index date. Body mass index (BMI) closest to the date of
25OHD measurement was obtained from EHR.
Total serum 25OHD was measured using liquid chromatography, tandem mass spectrometry.
The sensitivity of the assay is <2.5nmol/L. The intra-and inter-assay coefficients of variation are less
than 5·2% at 25, 62·5 and 192·5 nmol/L.
2.3. Genotyping
DNA samples were genotyped for two common single-nucleotide polymorphism (SNPs) in the
coding region of the vitamin D-binding protein gene (rs7041 and rs4588) located on chromosome 4.
These SNPs were selected because they are established markers of DBP phenotype and vary by race [8].
HLA-DRB1*15:01 status was determined using a tag SNP (rs3135388). Genetic ancestry was determined
with the software STRUCTURE Version 2.3.1, University of Oxford, Oxford, United Kingdom [17] using
a genome-wide set of 67,547 linkage disequilibrium pruned loci selected by PLINK 1.07, Center for
Human Genetic Research, the Broad Institute of Harvard & MIT, Boston, USA [18] (see Appendix A).
2.4. Statistical Analysis
2.4.1. Sun Exposure
We used the most rigorous method available for assessing lifetime sun exposure. Specifically, we
calculated cumulative lifetime UVR for each participant by combining latitude of residence and usual
time outdoors obtained from a detailed residency calendar with ambient UVR levels obtained from
satellite-derived ground level estimates [19]. The average monthly UVR estimates for each participant
were summed from age 6 years to symptom onset/index date.
2.4.2. 25OHD and Genotype
To examine the relationship between the rs7041 or rs4588 genotype and serum 25OHD levels,
we used multivariable linear regression with log-transformed 25OHD (normal distribution) as the
dependent variable. The models were adjusted for age, sex, BMI, season of 25OHD measurement,
genetic ancestry, and case status.
2.4.3. 25OHD, UVR, Vitamin D-Binding Protein Genotype and MS
Multivariable unconditional logistic regression was used to simultaneously examine the
independent effects of 25OHD, cumulative lifetime UVR (KJ/m2) and the dominant genotypes of
rs7041 and rs4588 on MS/CIS by race/ethnicity. 25OHD was log-transformed and both cases’ and
controls’ values were deseasonalized by using residuals derived from multivariable linear regression
adjusted for season (April–September or October–March) and BMI at 25OHD measurement because
BMI had a strong association with 25OHD levels but not MS/CIS risk. The models were adjusted for
age, sex, genetic ancestry, smoking and HLA-DRB1*15:01 carrier status.
To determine whether the associations varied by rs7041 or rs4588 genotype, we tested the
multiplicative interaction of rs7041 with 25OHD or UVR and rs4588 with 25OHD or UVR separately
using the same model as their main effects. These initial models included all participants (blacks,
Hispanics and whites) and were adjusted for genetic ancestry, cumulative lifetime UVR and the
other pre-specified factors. Because a significant multiplicative interaction (pre-set at p < 0.05) was
detected for rs7041*25OHD (p = 0.016), this model was then stratified by race/ethnicity and dominant
rs7041 genotype.
Sensitivity analyses excluding vitamin D supplement users were conducted for all analyses.
Two-sample t-tests were used to compare means, Wilcoxon–Mann–Whitney test for non-normally
Nutrients 2018, 10, 184 4 of 12
distributed variables and χ2 or Fisher exact test to compare frequencies between two groups.
All analyses were conducted using SAS software v9.3 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Characteristics of Participants
Table 1 shows the distribution of alleles in two common SNPs in the vitamin D-binding protein
gene (rs7041 and rs4588), HLA-DRB1*15:01 (rs3135388), 25OHD levels, cumulative UV dose and
the proportions of genetic ancestry in the three racial/ethnic groups, along with demographic
characteristics, prevalence of MS risk factors and selected factors that influence 25OHD levels.
The allele distribution for these SNPs did not differ significantly between cases and controls in blacks,
Hispanics or whites. As anticipated, carrying at least one copy of HLA-DRB1:15:01 (rs3135388-A allele)
was more common in cases than controls particularly in whites and Hispanics.
3.2. Polymorphisms in the Vitamin D-Binding Protein Gene and 25OHD
Whites and Hispanics were far more likely than blacks to carry at least one copy of the C allele at
rs7041 whereas blacks were more likely than whites or Hispanics to carry an A allele at this location.
The A allele at rs7041 was associated with lower 25OHD levels in all three groups but this reached
statistical significance only in whites (Table 2). Sensitivity analyses excluding vitamin D supplement
users showed similar results (see Appendix A).
The G allele was the dominant allele at rs4588 for all three groups, but whites and Hispanics were
less likely to carry this allele and more likely to carry at least one copy of the T allele at rs4588 than
blacks. The T allele at rs4588 was associated with significantly lower 25OHD levels in all three groups
(Table 2).
3.3. Polymorphisms in the Vitamin D-Binding Protein Gene, 25OHD, Cumulative Lifetime UVR and MS
An interaction, indicating that higher serum 25OHD levels and carrying at least one copy of the C
allele at rs7041 (p = 0.016) but not rs4588 was associated with lower MS risk, was detected in models
of all participants (blacks, Hispanics and whites pooled) independent of the effects of lifetime UVR
exposure, genetic ancestry, rs3135388, sex, age and smoking. In models stratified by race/ethnicity,
higher serum 25OHD levels were strongly associated with a lower risk of MS/CIS in whites who
carried at least one copy of the C allele at rs7041 (n = 406, 79.0%) but not in those homozygous for the A
allele. However, no association was found between 25OHD and MS in Hispanics or blacks regardless
of rs7041 genotype (Figure 1A).
We did not detect a significant interaction of cumulative UVR and the rs7041 or rs4588 genotype
in models that included all participants. However, the protective effect of cumulative UVR did appear
to be more pronounced in those carrying at least one copy of the C allele at rs7041. Higher lifetime UVR
exposure was associated with a significantly lower risk of MS (independent of 25OHD levels) in blacks
and Hispanics who carried at least one copy of the C allele at rs7041 (30.0% and 77.2% respectively) but
not in those homozygous for the A allele (Figure 1B). In whites, the magnitude of association between
UVR exposure and MS risk was similar in both genotypes but did not reach statistical significance in
the smaller group (21%) homozygous for the A allele at rs7041. These findings in whites likely explain
the failure to detect a significant interaction between UVR exposure and the rs7041 genotype in models
of all participants.
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Table 1. Selected characteristics at symptom onset/index date of MS/CIS cases and controls by race/ethnicity.
Black (n = 247) Hispanic (n = 380) White (n = 514)
Case (n = 116) Control (n = 131) p * Case (n = 183) Control (n = 197) p * Case (n = 247) Control (n = 267) p *
Age, mean (SD), y 38.4 (12.8) 38.5 (13.0) 0.93 32.5 (10.7) 32.6 (11.1) 0.95 39.7 (12.0) 39.9 (12.2) 0.87
Female, n (%) 92 (79.3) 103 (78.6) 0.90 132 (72.1) 145 (73.6) 0.75 164 (66.4) 174 (65.2) 0.77
Smoking, n (%) 27 (23.3) 33 (25.2) 0.73 44 (24.0) 38 (19.3) 0.26 115 (46.6) 90 (33.7) 0.003
BMI, mean (SD) 30.5 (7.4) 31.6 (8.1) 0.26 29.5 (6.8) 30.1 (7.0) 0.42 28.5 (6.7) 28.5 (6.9) 0.95
VitD supplement users *, n (%) 28 (24.1) 2 (1.5) <0.001 30 (16.4) 3 (1.5) <0.001 62 (25.1) 19 (7.1) <0.001
Season **, n (%) 56 (48.3) 65 (49.6) 0.83 85 (46.5) 104 (52.8) 0.22 116 (47.0) 142 (53.2) 0.16
cumulative UV dose ***, 1000 KJ/m2, mean (SD) 1.43 (0.77) 1.63 (0.79) 0.05 1.14 (0.61) 1.22 (0.68) 0.22 1.53 (0.79) 1.64 (0.83) 0.15
serum 25OHD, nmol/L, median (IQR) 43.7 (32.4,74.9) 47.4 (30.0,64.9) 0.53 54.9 (42.4,69.9) 57.4 (44.9,69.9) 0.35 67.4 (49.9,87.4) 72.4 (59.9,92.4) 0.003
Vitamin D-Binding Protein
rs7041, n (%) 0.53 0.64 0.37
AA 79 (68.1) 94 (71.7) 40 ( 21.9) 47 (23.8) 56 (22.7) 52 (19.4)
AC 32 (27.6) 31 (23.7) 93 (50.8) 100 (50.8) 116 (47.0) 123 (46.1)
CC 5 (4.3) 6 (4.6) 50 (27.3) 50 (25.4) 75 (30.3) 92 (34.5)
rs4588, n (%) 0.13 0.52 0.44
GG 96 (82.8) 98 (74.8) 110 (60.1) 112 (56.8) 122 (49.4) 141 (52.8)
GT 18 (15.5) 29 (22.1) 66 (36.1) 75 (38.1) 105 (42.5) 99 (37.1)
TT 2 (1.7) 4 (3.1) 7 (3.8) 10 (5.1) 20 (8.1) 27 (10.1)
HLA-DRB1*1501, n (%) 0.20 0.0002 <0.0001
GG 95 (81.9) 115 (87.8) 134 (73.2) 174 (88.3) 136 (55.1) 214 (80.1)
AG 21 (18.1) 15 (11.5) 47 (25.7) 19 (9.7) 92 (37.2) 52 (19.5)
AA 0 (0.0) 1 (0.8) 2 (1.1) 4 (2.0) 19 (7.7) 1 (0.4)
Ancestry % median (IQR)
European 21.2 (14.6, 28.0) 22.8 (16.3, 31.9) 58.6 (50.1, 66.0) 56.6 (48.5, 64.3) 99.0 (97.6, 99.7) 99.1 (97.6, 99.8)
African 77.6 (69.8, 84.4) 75.4 (66.2, 83.0) 5.1 (3.8, 6.9) 4.9 (3.8, 6.4) 0.1 (0.0, 0.9) 0.0 (0.0, 0.8)
Amerindian 0.3 (0.1, 1.4) 0.7 (0.2, 1.9) 35.7 (27.0,42.8) 38.0 (31.0, 46.1) 0.5 (0.2, 1.1) 0.4 (0.2, 1.2)
MS = multiple sclerosis, CIS = clinically isolated syndrome, SD = standard deviation, IQR = interquartile range, BMI = body mass index, VitD = vitamin D, UV = ultraviolet radiation;
y = years. * At the time of 25OHD measurement; ** season (April–September) at the time of 25OHD measurement; *** from age 6 years to index date.
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Table 2. Association of vitamin D-binding protein genetic polymorphisms and serum 25OHD levels by
race/ethnicity.
Race/Ethnicity SNP n ReferenceAllele
Variant
Allele
Variant
Allele
Frequency
β Estimate *
Change in Total
25OHD Level Per
Variant Allele Copy
(95% CI), nmol/L
p
Black rs7041 247 C A 0.828 −0.1136 −5.5 (−11.9 to 0.2) 0.0573
Hispanic rs7041 380 C A 0.483 −0.0492 −2.7 (−5.9 to 0.3) 0.0757
White rs7041 514 C A 0.443 −0.0813 −5.9 (−9.3 to −2.7) 0.0002
Black rs4588 247 G T 0.119 −0.2148 −8.9 (−13.5 to −3.7) 0.0014
Hispanic rs4588 380 G T 0.230 −0.0836 −4.4 (−7.6 to −0.9) 0.0135
White rs4588 514 G T 0.290 −0.1160 −7.7 (−10.5 to −4.7) <0.0001
25OHD = 25-hyrdoxyvitamin D, CI = confidence intervals; * adjusted for age, sex, BMI, season of 25OHD
measurement, smoking, genetic ancestry and case status.
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Figure 1. Vitamin D-Binding Protein Genotype, Ultraviolet radiation exposure, 25-Hydroxyvitamin
D and MS. Depicted are the odds ratios (ORs) and 95% confidence intervals (CIs) of the independent
associations of serum 25-hydroxyvitamin D levels (Panel A) or cumulative lifetime ultraviolet radiation
exposure (Panel A) with risk of multiple sclerosis/clinically isolated syndrome stratified by dominant
genotype of SNP rs7041 within each racial/ethnic group. Serum 25-hydroxyvitamin D levels were
log transformed and adjusted for BMI and season. Odds ratios are adjusted by age, sex, smoking,
genetic ancestry, HLA-DRB1*15:01 (rs3135388) 25-hydroxyvitamin D (Panel A) or lifetime ultraviolet
radiation exposure (Panel B). In blacks, AA is the most common genotype (n = 173, 70.0%; AC/CC
n = 74, 30.0%). Among Hispanics, the distribution is AA n = 87, 22.9% and AC/CC n = 293, 77.1%;
in whites, AA n = 108, 21.0% and AC/CC n = 406, 79.0%.
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4. Discussion
That common polymorphisms in the vitamin D-binding protein gene could modify the
relationship between vitamin D and MS risk in blacks and whites is biologically plausible. Vitamin
D-binding protein is the main transporter of 25OHD and its metabolites. SNPs in the gene encoding
DBP at rs7041 and to a lesser extent rs4588 influence bioavailable fractions because they result in DBP
isoforms that have different avidity for 25OHD and its metabolites [9]. The dominant allele at rs7041
in whites is the minor allele in blacks. The resulting DBP isoform most commonly found in blacks
has the highest avidity and is the most efficient transporter of 25OHD and its metabolites to target
tissues [9]. It is also associated with higher ‘free’ or bioavailable 25OHD levels which may explain
why, despite quite low total 25OHD levels, most blacks are not physiologically vitamin D deficient [7].
Following this line of reasoning, we hypothesized that these known racial differences in the prevalence
of common genetic polymorphisms in the vitamin D-binding protein gene could explain why we and
others [5] have been unable to detect an association between 25OHD and MS risk in blacks.
Yet, the analyses presented herein demonstrate that racial/ethnic variations in bioavailable
vitamin D resulting from differences in dominant polymorphisms in the vitamin D-binding protein
gene do not explain the lack of association between 25OHD and MS in blacks and Hispanics. Taken
together with our previously reported findings that higher levels of UVR exposure from sunshine are
independently and consistently associated with lower MS risk across all 3 racial/ethnic groups [7],
these findings further challenge the biological plausibility of vitamin D deficiency as causal for MS.
While it may be tempting to cling to the idea that somehow vitamin D is causally linked to MS
risk in whites but just not in blacks and Hispanics, it is difficult to conceive how a factor could be
causal in only one racial/ethnic group. One could contend that the consistently protective effect of
UVR across all three groups is still ultimately mediated by vitamin D, but that serum 25OHD is the
wrong measure of vitamin D status in blacks and Hispanics. However, there are several problems with
this line of reasoning: (1) the common polymorphisms we measured are in coding regions and directly
influence the bioavailable fraction of 25OHD and its metabolites; (2) the prevalence of these common
polymorphisms in whites and Hispanics are almost identical yet we cannot establish a relationship
between MS risk and 25OHD in Hispanics. Furthermore, other studies of Hispanics with MS have
reported that 25OHD levels do not differ between prevalent cases or controls [20], or decline with
increasing disability as has been shown in whites [21]; (3) There is increasing evidence that UVR causes
a plethora of immunological changes including effects that could influence autoimmune diseases
independent of vitamin D. These include generation of T regulatory cells, B suppressor (regulatory)
cells and production of immunosuppressive lipid mediators and alarmins [22] as well as suppression of
the animal model of MS (experimental autoimmune encephalomyelitis) [23–25]. Lastly (4), the amount
of UVR exposure, while consistently associated with MS risk, is strongly related to latitude of residence.
It is important to remember that the vitamin D-MS hypothesis originated from the observation that
the prevalence of MS is higher at latitudes further away from the equator where the intensity of UVR
exposure is lower. However, UVR may not be the only reason for the observed latitude gradient as
there are other potential MS risk factors that traditionally varied with latitude, including endemic
infectious agents, food sources and genetic make-up of native inhabitants.
Our data are consistent with previous studies that examined the relationship between vitamin
D-binding protein genotype and serum 25OHD levels in blacks, Hispanics and whites [6,7,22–24].
We found similar distributions of rs7041 and rs4588 polymorphisms and similar associations of these
genes with lower 25OHD levels across all three groups [7,22–24]. Our findings are also consistent with
the results of randomized controlled trials that have failed to demonstrate convincing health benefits
of vitamin D supplementation [26–28] in other diseases.
Intriguingly, we also found that the strong association of higher sun exposure and lower MS risk
in blacks, Hispanics and whites is most pronounced in those individuals who carry at least one copy of
the C allele at rs7041. This difference is most noticeable in blacks even though only 30.4% carry at least
one C allele at this location. We think this stronger effect in blacks may be because they are less likely
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to use sunscreen than whites; thus blacks effectively get more sun exposure for the same amount of
time outdoors at a particular ambient UVR than whites. We cannot exclude the possibility that this is a
chance finding, as we did not detect a significant multiplicative interaction between UVR and rs7041
in the pooled cohort where only genetic ancestry and not self-reported race/ethnicity was considered.
Rather, this association was uncovered when we examined the results of the stratified models that
were run after detecting an interaction between 25OHD and rs7041 in the pooled cohort.
Alternatively, we speculate that the different DBP isoforms may have novel interactions with the
immunomodulatory effects of UVR independent of vitamin D. Aside from transporting vitamin D,
DBP also directly influences macrophage and neutrophil function and plays a role in tissue injury
and repair [10]. Only 5% of the binding sites on DBP are occupied by vitamin D, implying that this
protein’s major role may be through other actions [10]. UVR exposure results in immunomodulation
through multiple mechanisms, many of which are independent of vitamin D. Such a non-classical
interaction between DBP and UVR would be a more satisfying unifying explanation of our findings.
Yet the evidence supporting such an interaction is lacking as no studies directly address the role of
DBP in photoimmunology and very few studies have examined whether specific DBP genotypes are
associated with differences in other DBP functions such as macrophage activation [10].
If this finding can be replicated, it would have wide-reaching implications for the role of vitamin
D in MS and other disease states as it implies that variation in the DBP genotype may affect MS risk
through a vitamin D-independent pathway. Such a finding would invalidate the current instruments for
Mendelian randomization studies of vitamin D because it violates the assumption that the genotypes
affect the risk of disease only through influencing vitamin D status. This has important implications
for the MS-vitamin D hypothesis, as Mendelian randomization studies are the strongest evidence to
date to support a causal relationship between 25OHD and MS risk in whites. The main limitation of
this study is that we were unable to identify an existing cohort of blacks or Hispanics with incident MS
and sun exposure, 25OHD measurements and genotype in which these findings could be replicated.
We also cannot exclude the possibility that we are underpowered to detect a protective association
with 25OHD and MS in the small subgroups of white or Hispanic AA carriers and black carriers of
AC/CC. Other limitations of this study include the case-control design necessitating that most 25OHD
measures were obtained after symptom onset (although very close to the time of diagnosis). MS often
results in sun avoidant behavior due to heat sensitivity which can cause an exaggerated association
between low 25OHD and MS particularly in prevalent cases. This most likely explains the observed
lower 25OHD levels in a previous study of prevalent black MS cases compared to controls [29] and
may explain the strong association we found in whites, but does not explain the lack of association we
found in Hispanics and blacks. Likewise, multiple statistical tests would be expected to lead to false
positive results rather than consistently negative findings. Data on sunscreen use over the life course
were limited. Sunscreen is more likely to have been used by whites than other racial groups (since
they are more sun sensitive), and regular and correct use of a high SPF sunscreen would reduce the
effective UVR exposure of the skin. Thus, our effect estimates presented herein likely underestimate
the protective effect of the received UVR dose in whites.
This study highlights how multi-ethnic studies can lead to novel insights into disease. Important
racial variations in the gene encoding DBP do not explain the lack of association between 25OHD and
MS risk in blacks and Hispanics, yet higher levels of UVR may be particularly important in protecting
against the risk of MS in those carrying the DBP dominant in whites. Replication of our key findings
should be addressed in future studies.
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Appendix A
Appendix A.1. Supplementary Methods
Appendix A.1.1. Study Population, Case and Control Identification and Recruitment
KPSC provides comprehensive health care to ~20% of the population in the geographic area
it serves [11]. To identify potentially eligible cases, we searched the complete electronic health
record (EHR) electronically monthly for first mention of ICD-9 diagnostic codes for MS or CIS
1 January 2011–31 December 2014. Diagnoses were confirmed by an MS specialist (ALG) after
complete EHR review according to revised McDonald criteria for MS [14] and consensus definitions
for idiopathic transverse myelitis (TM) [15,16]. All diagnoses of optic neuritis (ON) were confirmed by
ophthalmologists. Symptom onset date and date of diagnosis were validated by structured interview.
Patients who met diagnostic criteria for neuromyelitis optica spectrum disorder [30] were excluded.
Due to resource limitations and because the primary goal was to study non-white populations,
recruitment of white cases was stopped after the target of n = 250 had been reached. Study subjects of
Asian/Pacific Islander (56 subjects) and Multiple (2 subjects) races were excluded from the analyses
due to small sample size. We plan on examining Asian/Pacific Islanders separately once we have
recruited sufficient number of participants as we expect the effects of vitamin D and sun exposure on
the risk of MS to differ from blacks and whites.
There are slightly more controls in the MS Sunshine Study than cases primarily because sometimes
the race/ethnicity indicated in the EHR did not match the participant’s self-reported race/ethnicity.
This mis-match between the EHR and self-reported race/ethnicity occurred primarily with white,
Hispanics and white, non-Hispanics. To identify eligible controls matched to cases on race/ethnicity,
race/ethnicity was initially pulled electronically from the EHR. If, during the structured in-person
interview, the control reported a different race/ethnicity than their respective case, another control
was recruited for the case until a true racial/ethnic match was completed. Asians (total cases and
controls n = 57) and people of multiple races (n = 2) were recruited but not included in the analyses
due to small sample.
Appendix A.1.2. Genotyping
The genotyping data was available on 1159 (97.6%) of the 1187 black, Hispanic or white subjects
who had completed the study protocol by 6/2/2015. Eighteen subjects were excluded due to missing
phenotype data as follows: 5 due to missing serum 25(OH) D values; 11 for missing cumulative UVR
data; and 2 for missing smoking status. The final analysis cohort included 1141 (96.1%) subjects:
247 Blacks (116 cases/131 controls), 380 Hispanics (183 cases/197 controls) and 514 whites (247 cases/
267 controls).
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These subjects were genotyped successfully for 697,895 SNPs using Illumina’s
HumanOmniExpressExome v1.2. DNA Analysis BeadChips were produced by the Vincent J.
Coates Genomics Sequencing Laboratory (GSL) at the University of California, Berkeley. DNA samples
were quantitated using the Nanodrop ND-1000 and subsequently normalized and plated for
processing. The samples were processed using the Illumina Infinium HD Assay Super protocol.
DNA samples were denatured, neutralized, and prepared for amplification. The amplified product
was then fragmented, precipitated, and collected by centrifugation. The precipitated DNA was
resuspended in hybridization buffer and subsequently hybridized to a beadchip. The beadchip was
then prepared for extension and staining. Once the assay was completed, the chips were dried and
placed on the scanner for data collection. Data was then QC’d using Genome Studio and Plink.
From Within GenomeStudio, various QC measures were checked including call rates, sex
discrepancies, reproducibility and heritability of replicates and CEPH control trios, as well as
performance of internal Illumina controls. Any samples with the above discrepancies were noted
down. Samples with call rates of less than 90% or less than 99% were also noted. In addition, the
following data from PLINK1.07 [18] were filtered: N/percent of SNPs with call-rate <90%, N/percent
of SNPs with Hardy Weinberg (all samples) p-value < 1 × 10−6, N/percent of SNPs with MAF < 0.01.
A summary of Control target intensities was then created to evaluate the performance of Illumina’s
internal controls. Illumina includes several control targets for the purpose of QC at various stages.
The Staining, Extension, Target Removal, and Hybridization controls are all sample-independent
measures that show the performance of the assay. The Stringency, Non-Specific Binding and
Non-Polymorphic controls are all sample-dependent controls.
We performed sex check and tested the deviation from Hardy–Weinberg equilibrium within
racial/ethnic group on SNPs using PLINK 1.07.
Appendix A.2. Ancestry Structure
To investigate genetic ancestry, the software STRUCTURE Version 2.3.1 [17] was used to infer
the presence of distinct populations. A genome-wide set of 67,547 linkage disequilibrium pruned
loci were selected using PLINK. We compared the structure outputs from three (Europeans, Africans,
and Amerindians), five (Europeans, Africans, Amerindians, East Asians, and Central/South Asians),
and seven (Europeans, Africans, Amerindians, East Asians, Central/South Asians, Western Asians
and Oceanians) reference populations, and concluded that using five or seven reference populations
did not improve upon the three population model for estimating population admixture in our cohort.
With three populations assumed, the probability of population ancestry was estimated by specifying
a 10,000 iteration burn-in period and a 10,000 iteration follow-up of the Markov Chain Monte Carlo
model utilized by STRUCTURE.
Appendix A.3. Deseasonalized 25OHD Values for Other Analyses
For analyses that include unmatched cases and controls, 25OHD levels were deseasonalized
for both cases and controls and did not result in significantly different findings. Seasons were
combined into two seasons, winter (October–March) and summer (April–September) based on the
inflection points of the best-fit polynomial regression (quadratic function) of the monthly variation
of 25OHD values among controls. This is consistent with Southern California’s annual fluctuation in
temperatures and daylight hours. We did not detect significant variation between fall and winter or
spring and summer.
Appendix A.4. Cumulative Lifetime UVR
Cumulative lifetime UVR for each participant was calculated using previously validated
methods [1]. Average monthly estimates derived by linking latitude and longitude of residence
with satellite-derived ground level estimates of ambient UVR multiplied by proportion of time in
the sun during summer were summed from age 6 years to symptom onset/index date. Specifically,
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we used the proportion of self-reported hours outside in the sun for weekends (26 days) and holidays
(14 days) in the season (summer: (sun time in hour/12) * 40 to calculate the personal cumulative
leisure-time UVR dose in summer for each participant. The leisure-time UVR dose was calculated as
ambient UV x proportion of days in the sun, then summed over the relevant period, from 6 years of
age until symptom onset/index date.
Appendix A.5. Supplementary Results
Table A1. Sensitivity analysis: Association of Vitamin D-binding protein Genetic Polymorphisms and
serum 25OHD levels by race/ethnicity excluding subjects using vitamin-D supplements at the time of
25OHD measurement.
Race/Ethnicity SNP n ReferenceAllele
Variant
Allele
Variant
Allele
Frequency
B Estimate *
Change in Total
25OHD Level Per
Variant Allele Copy
(95% CI), nmol/L
p
Black rs7041 217 C A 0.825 −0.1322 −6.3 (−13.1 to −0.4) 0.0358
Hispanic rs7041 347 C A 0.488 −0.0490 −2.8 (−5.9 to 0.3) 0.0733
White rs7041 433 C A 0.441 −0.0675 −4.9 (−8.4 to −1.5) 0.0044
Black rs4588 217 G T 0.124 −0.2290 −9.2 (−13.7 to −4.1) 0.0009
Hispanic rs4588 347 G T 0.232 −0.0933 −4.9 (−8.1 to −1.5) 0.0052
White rs4588 433 G T 0.281 −0.1191 −7.9 (−10.9 to −4.6) <0.0001
25OHD = 25-hyrdoxyvitamin D, CI = confidence intervals; * adjusted for age, sex, BMI, season of 25OHD
measurement, smoking, genetic ancestry and case status.
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